Efficacy News and Research

RSS

Study: Early stuttering not linked to development issues

A study of over 1600 children, which followed the children from infancy to four years old, found the cumulative incidence of stuttering by four years old was 11 per cent, more than twice what has previously been reported.

27 Aug 2013

Researchers develop therapeutic algorithm to study outcomes in epistaxis management

Approximately 60 percent of people experience epistaxis, commonly known as nosebleed, at least once in their lifetime. Of those who experience nosebleed, six percent require medical treatment. A study in the September 2013 issue of Otolaryngology-Head and Neck Surgery, explores which nosebleed treatment options demonstrate the best outcomes.

27 Aug 2013

Mount Sinai scientists receive NIH grant to study clinical benefit of IGF-1 in children with PMS

Scientists at the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai have received a grant from the National Institutes of Health to study Insulin-Like Growth Factor-1, a promising treatment for a subtype of autism called Phelan McDermid Syndrome.

27 Aug 2013

Sanofi Pasteur reports clinical benefit of Fluzone High-Dose vaccine in preventing influenza

Sanofi Pasteur, the vaccines division of Sanofi, today announced topline results of a large-scale, multi-center efficacy trial in people 65 years of age and older showing a superior clinical benefit of Fluzone High-Dose (Influenza Virus Vaccine) relative to the standard dose of Fluzone vaccine in preventing influenza.

26 Aug 2013

Sangamo BioSciences signs definitive agreement to buy Ceregene

Sangamo BioSciences, Inc. announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus gene therapies.

26 Aug 2013

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Immune Pharmaceuticals Inc. announced today the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation.

26 Aug 2013

Scientists receive NIH grant to study commercially-available drug for treatment of PMS

Scientists at the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai have received a grant from the National Institutes of Health (NIH) to study Insulin-Like Growth Factor-1 (IGF-1), a promising treatment for a subtype of autism called Phelan McDermid Syndrome (PMS).

26 Aug 2013

Scanning technique reveals how brain tumor responds to drug administered

A new scanning technique developed by Danish and US researchers reveals how susceptible patients with aggressive brain cancer are to the drugs they receive. The research behind the ground-breaking technique has just been published in Nature Medicine.

26 Aug 2013

Stem cell therapy improves radiation-induced cognitive impairment

Patients receiving cranial irradiation treatment for brain cancer may find the treatment life-saving, but often suffer progressive and debilitating cognitive detriments, including spatial learning and memory deficits. The cognitive deficits are a contributing factor to the often significant adverse impacts on the surviving patients' quality of life after radiation therapy. In an effort to improve post-irradiation cognitive impairment, scientists at the University of California, Irvine, and colleagues at Neuralstem, Inc. (Rockville, MD), have transplanted fetal stem cells into laboratory animals with radiation-induced cognitive impairments and found that this led to a number of cognitive improvements.

23 Aug 2013

Navidea Biopharmaceuticals signs SPA agreements with FDA for NAV5001 Phase 3 program

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has reached agreement with the U.S. Food and Drug Administration for two special protocol assessments for the Company's pivotal Phase 3 program with NAV5001 as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor.

23 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

Low-cost intervention reduces transmission of lymphatic filariasis to undetectable levels

An international team of scientists have demonstrated that a simple, low-cost intervention holds the potential to eradicate a debilitating tropical disease that threatens nearly 1.4 billion people in more than six dozen countries.

22 Aug 2013

Use of psychotherapy on a clear decline in US

Psychotherapy has issues. Evidence shows that some psychosocial treatments work well for common mental health problems such as anxiety and depression and that consumers often prefer them to medication.

22 Aug 2013

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.

22 Aug 2013

Research suggests restricting calories may improve success of cancer treatment

New research suggests that restricting calories for a defined period of time may improve the success of cancer treatment, offering valuable new data on how caloric intake may play a role in programmed cancer cell death and efficacy of targeted cancer therapies. Study results were published online today in Blood, the Journal of the American Society of Hematology (ASH).

22 Aug 2013

HIV prevention program at UCLA may reduce unprotected sex among bisexual black men

A culturally tailored HIV prevention program developed and tested by investigators at UCLA and the Charles R. Drew University of Medicine and Science has been shown to significantly reduce unprotected sex among bisexual black men.

22 Aug 2013

Radiation Oncologist receives Young Investigator Award from PCF

Jefferson Radiation Oncologist, Nicole Simone, M.D., was recently awarded one of 21 Young Investigator Awards from the Prostate Cancer Foundation (PCF).

21 Aug 2013

Oncopeptides launches phase II study to determine efficacy of melflufen in treatement of multiple myeloma

Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).

21 Aug 2013

Lateral wedge insoles are not effective in reducing knee pain in osteoarthritis patients

Although a pooling of data from 12 studies showed a statistically significant association between use of lateral wedge insoles and lower pain in medial knee osteoarthritis, among trials comparing wedge insoles with neutral insoles, there was no significant or clinically important association between use of wedge insoles and reduction in knee pain, according to a study in the August 21 issue of JAMA.

21 Aug 2013

Twice-daily KALYDECO improves lung function in people with cystic fibrosis

Vertex Pharmaceuticals (Australia) Pty Ltd., announces the presentation of data from KALYDECO (ivacaftor) studies at the 10th Australasian Cystic Fibrosis Conference in Auckland, New Zealand, August 17 – 20, 2013, which further demonstrate the benefits of the medicine in people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

21 Aug 2013

Efficacy News and Research

Study: Early stuttering not linked to development issues

Researchers develop therapeutic algorithm to study outcomes in epistaxis management

Mount Sinai scientists receive NIH grant to study clinical benefit of IGF-1 in children with PMS

Sanofi Pasteur reports clinical benefit of Fluzone High-Dose vaccine in preventing influenza

Sangamo BioSciences signs definitive agreement to buy Ceregene

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Scientists receive NIH grant to study commercially-available drug for treatment of PMS

Scanning technique reveals how brain tumor responds to drug administered

Stem cell therapy improves radiation-induced cognitive impairment

Navidea Biopharmaceuticals signs SPA agreements with FDA for NAV5001 Phase 3 program

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Low-cost intervention reduces transmission of lymphatic filariasis to undetectable levels

Use of psychotherapy on a clear decline in US

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Research suggests restricting calories may improve success of cancer treatment

HIV prevention program at UCLA may reduce unprotected sex among bisexual black men

Radiation Oncologist receives Young Investigator Award from PCF

Oncopeptides launches phase II study to determine efficacy of melflufen in treatement of multiple myeloma

Lateral wedge insoles are not effective in reducing knee pain in osteoarthritis patients

Twice-daily KALYDECO improves lung function in people with cystic fibrosis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News